SCOTTSBLUFF, Neb., – Weight Loss Options at Regional West is pleased to announce that the U.S. Food and Drug Administration has approved ORBERA™ to assist adult patients suffering from obesity, with a body mass index of 30 to 40 BMI, in losing and maintaining weight.

The OBERA™ balloon is part of the ORBERA™ Managed Weight Loss System, a comprehensive, non-surgical two-part program that includes a balloon filling space in a patient’s stomach to reinforce proper portion control. Data on ORBERA™ collected in the U.S. clinical trial has shown that the average person lost 3.1 times the weight within six months as compared with diet and exercise alone.

Regional West will be one of the first hospitals in the country to offer this new tool for helping people achieve their weight loss goals.

ORBERA™ is a safe and effective weight loss solution with 20 years of global experience and real world results. More than 220,000 ORBERA™ balloons have been distributed worldwide in over 80 countries.

Recognizing that obesity is a chronic disease, Regional West offers new, minimally invasive solutions, like OBERA™, to help transform the lives of patients before their disease progresses and requires more invasive treatment.

For additional information regarding ORBERA™, please visit orbera.com and orbera.com/dfu. For more information on ORBERA™ at Regional West, please visit rwhs.org/weightlosssurgery.

Regional West Health Services in Scottsbluff, Neb., is the parent company of Regional West Medical Center, a 182-bed regional referral center and one of three Level II Trauma Centers in the state. As the region’s only tertiary referral medical center, Regional West offers care that spans more than 32 medical specialties provided by over 28 physician clinics. With nearly 300 providers, and over 2,000 employees, Regional West provides comprehensive and innovative health care services for the people of western Nebraska and the neighboring states of Colorado, South Dakota, and Wyoming.